An open, randomized, multicenter clinical trial of oral tacrolimus in liver allograft transplantation: A comparison of dual vs. triple drug therapy

Liver Transplantation

Volumn 11, Issue 5, 2005, Pages 515-524

  García González, Miguel ^a   Pera Madrazo, Carlos ^b   Bernardos Rodríguez, Ángel ^c   Gómez Gutiérrez, Manuel ^d   Ignacio Herrero, J ^e   Mir Pallardó, José ^f   Ortiz de Urbina, Jorge ^g   Parrilla Paricio, Pascual ^h  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^c HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^d HOSPITAL JUAN CANALEJO   (Spain)

^e UNIVERSITY CLINIC OF NAVARRA   (Spain)

^f HOSPITAL UNIVERSITARIO LA FE   (Spain)

^g HOSPITAL DE CRUCES   (Spain)

^h HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; INSULIN; METHYLPREDNISOLONE; TACROLIMUS;

ACUTE GRAFT REJECTION; ADULT; ALLOTRANSPLANTATION; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE RESISTANCE; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GRAFT SURVIVAL; HEMATOLOGIC DISEASE; HEPATITIS C; HUMAN; HYPERGLYCEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; KIDNEY DYSFUNCTION; LEUKOPENIA; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SCLEROSING CHOLANGITIS; SINGLE DRUG DOSE; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT FAILURE;

ADMINISTRATION, ORAL; ADRENAL CORTEX HORMONES; AGED; AZATHIOPRINE; DRUG THERAPY, COMBINATION; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; TACROLIMUS; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 18944367130     PISSN: 15276465     EISSN: None     Source Type: Journal    
DOI: 10.1002/lt.20382     Document Type: Article

References (32)

1. Goto T, Kino T, Hatanaka H, Nishiyama M, Okuhara M, Kohsaka M, et al. Discovery of FK506, a novel immunosuppressant isolated from Streptomyces tsukubaensis. Transplant Proc 1987;19:4-8.
2. Ochiai T, Nakajima K, Nagata M. Effect of a new immunosuppressive agent, FK506, on heterotopic cardiac allotransplantation in the rat. Transplant Proc 1987;19:1284-1286.
3. Zeevi A, Duquesnoy R, Eiras G, Todo S, Makowka L, Starzl T. In vitro immunosuppressive effects of FR 900506 on human T lymphocyte alloactivation. Surg Res Comm 1987;1:315-323.
4. Kay JE, Moore AL, Doe SEA, Benzie CR, Schoenbrunner R, Schmid FX, et al. The mechanism of action of FK506. Transplant Proc 1990;22:96-100.
5. Thomson AW. Interspecies comparison of the immunosuppressive efficacy and safety of FK506. Transplant Proc 1990;22:100-106.
6. Zeevi A, Eiras G, Bach FH, Fung JJ, Todo S, Starzl T, et al. Functional differentiation of human cytotoxic T-lymphocytes in the presence of FK506 and CyA. Transplant Proc 1990;22:106-109.
7. Morris RE, Wu J, Shorthouse R. Comparative immunopharmacologic effects of FK506 and CyA in vivo models of organ transplantation. Transplant Proc 1990;22:110-112.
8. Todo S, Demetris AJ, Ueda Y, Imventarza O, Okuda K, Casavilla A, et al. Canine kidney transplantation with FK506 alone or in combination with cyclosporin and steroids. Transplant Proc 1987;19:S57-S61.
9. Todo S, Ueda Y, Demetris AJ, Imventarza O, Nalesnik M, Venkataramanan R, et al. Immunosuppression of canine, monkey and baboon allografts by FK506 with special reference to synergism with other drugs and to tolerance induction. Surgery 1988;104:239-249.
10. Tsuchimoto S, Kusumoto K, Nakajima Y, Kakita A, Uchino J, Natori T, et al. Orthotopic liver transplantation in rats receiving FK506. Transplant Proc 1989;21:1064-1065.
11. Todo S, Podesta L, ChapChap P, Kahn D, Pan CE, Ueda Y, et al. Orthotopic liver transplantation in dogs receiving FK506. Transplant Proc 1987;19:S64-S67.
12. Fung J, Abu-Elmagd K, Jain A, Gordon R, Tzakis A, Todo S, et al. A randomized trial of primary liver transplantation under immunosuppression with FK 506 vs cyclosporine. Transplant Proc 1991;23:2977-2983.
13. European FK506 Multicentre Liver Study Group. Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. Lancet 1994;344:423-428.
14. U.S. Multicenter FK506 Liver Study Group. Comparison of FK506 and cyclosporine for immunosuppression in liver transplantation. N Engl J Med 1994;331:1110-1115.
15. Neuhaus P, Langrehr JM, Williams R, Calne RY, Pichlmayr R, McMaster P. Tacrolimus-based immunosuppression after liver transplantation: a randomised study comparing dual versus triple low-dose oral regimens. Transpl Int 1997;10:253-261.
16. Bárcena R, López-San Román A, García M, Ruiz del Árbol L, De Vicente E, Candela A. Immunosuppression in liver transplantation: a European survey. Transplant Proc 1999;31:2427-2428.
17. Serrano J, González MG, Gómez M, Ortiz de Urbina J, Cillero PL, San Juan F, et al. Tacrolimus is effective in both dual and triple regimens after liver transplantation. Transplant Proc 2002; 34:1529-1530.
18. Boillot O, Baulieux J, Wolf P, Messner M, Cherqui D, Gugenheim J, et al. Low Rejection rates with tacrolimus-based dual and triple regimens following liver transplantation. Clin Transplant 2001;15:159-166.
19. Salizzoni M, Cavaliari A, Risalti A, Filipponi F, Gerunda GE, Forti D, et al. Tacrolimus based dual therapy is as efficacious and safe as the conventional tacrolimus based triple therapy in liver transplantation. Transplant Proc 2001;33:2258-2262.
20. Wiesner RH, Demetris AJ, Belle SH, Seaberg EC, Lake JR, Zetterman RK, et al. Acute hepatic allograft rejection: incidence, risk factors and impact on outcome. Hepatology 1998;28:638-645.
21. Berenguer M, Wright TL. Hepatitis C and liver transplantation. Gut 1999;45:159-163.
22. Crosbie OM, Alexander GJM. Liver transplantation for hepatitis C virus related cirrhosis. Baillieres Clin Gastroenterol 2000;14: 307-325.
23. Berenguer M, López-Labrador FX, Wright TL. Hepatitis C and liver transplantation. J Hepatol 2001;35:666-678.
24. Guido M, Faginoli S, Tessari G, Burra P, Leonardo G, Boccagni P, et al. Histology predicts cirrhotic evolution of post transplant hepatitis C. Gut 2002;50:697-700.
25. Mueller AR, Olatz KP, Bechstein WO, Blumbardt G, Lobeck H, Hop V, et al. Increased rejection after liver transplantation in FK 506-treated patients is associated with viral hepatitis C disease. Transplant Proc 1994;26:3637-3639.
26. Brillanti S, Vivarelli M, de Ruvo N, Aden AA, Camaggi V, D'Errico A, et al. Slow tapering of steroids protects the graft against hepatitis C recurrence after liver transplantation. Liver Transpl 2002;8:884-888.
27. Jain A, Reyes J, Kashyap R, Dodson SF, Demetris AJ, Ruppert K, et al. Long-term survival after liver transplantation in 4,000 consecutive patients at a single center. Ann Surg 2000;232:490-500.
28. Sheiner PA, Schwartz ME, Mor E, Schluger LK, Theise N, Kishikawa K, et al. Severe or multiple rejection episodes are associated with early recurrence of hepatitis C after orthotopic liver transplantation. Hepatology 1995;21:30-34.
29. Berenguer M, Prieto M, Cordoba J, Rayon JM, Carrasco D, Olaso V, et al. Early development of chronic active hepatitis in recurrent hepatitis C virus infection after liver transplantation: association with treatment of rejection. J Hepatol 1998;26:756-763.
30. Samuel D, Bismuth H, Boillot O, Ducerf C, Baulieux J, Gugenheim J, et al. Tacrolimus (FK506)-based dual versus triple therapy following liver transplantation. Transplant Proc 1998;30: 1394-1396.
31. Segoloni G, Bonomini V, Maresca MC, Arisi L, González-Molina M, Tarantino A, et al. Tacrolimus is highly effective in both dual and triple therapy regimens following renal transplantation. Spanish and Italian Tacrolimus Study Group. Transpl Int 2000; 13:S336-S340.
32. Ericzon B, Groth C, Bismuth H, Calne R, McMaster P, Neuhaus P, et al. Glucose metabolism in liver transplant recipients treated with FK 506 or cyclosporin in the European multicentre study. Transpl Int 1994;7:S11-S14.